Capricor's cell therapy shows three year benefit in DMD patients [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
The Phase II (NCT03406780) three-year open-label extension (OLE) study showed that deramiocel led to a 47% slowing of disease in skeletal muscle in patients with DMD. The trial, involving 12 patients on deramiocel, also showed improved measures of cardiac function, especially in patients that had higher ejection fractions (45%) at the beginning of the randomised portion of the trial. All patients encountered adverse events (AEs), with the majority being low grade, with 38.5% of events being Grade 3. There were no Grade 4 or Grade 5 events. This remains consistent with previous studies of deramiocel. Capricor says that the data supports the need for early intervention to maintain function and potentially slow the progression of cardiomyopathy, which is one of the leading causes of death in patients with DMD. Capricor CEO Dr Linda Marbán said: “The results of the open-label study are tremendously important for DMD patients, as they showed sustained skeletal and cardiac benefits
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesGlobeNewswire
- DMD clinical studies evolve with emphasis on building designs around relevant endpoints [Yahoo! Finance]Yahoo! Finance
- Things Look Grim For Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Today's Downgrade [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Analyst Actions
- 7/2/24 - HC Wainwright
CAPR
Sec Filings
- 8/23/24 - Form SC
- 8/23/24 - Form 3
- 8/9/24 - Form 4
- CAPR's page on the SEC website